Immunosensitization with a Bcl-2 small molecule inhibitor. [electronic resource]
- Cancer immunology, immunotherapy : CII May 2009
- 699-708 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1432-0851
10.1007/s00262-008-0592-4 doi
Animals Antigens, Neoplasm--immunology Apoptosis--drug effects Biphenyl Compounds--therapeutic use Cancer Vaccines--immunology Cell Line, Tumor--drug effects Colonic Neoplasms--immunology Cytotoxicity, Immunologic Dendritic Cells--immunology Drug Screening Assays, Antitumor Humans Immunotherapy--methods Immunotherapy, Adoptive Intramolecular Oxidoreductases--genetics Killer Cells, Lymphokine-Activated--transplantation Listeria monocytogenes--immunology Melanoma, Experimental--immunology Mice Mice, Inbred BALB C Mice, Inbred C57BL Neoplasm Proteins--antagonists & inhibitors Nitrophenols--therapeutic use Piperazines--therapeutic use Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors Receptors, Death Domain--agonists Recombinant Fusion Proteins--immunology Sulfonamides--therapeutic use TNF-Related Apoptosis-Inducing Ligand--pharmacology Tumor Necrosis Factor-alpha--pharmacology fas Receptor--pharmacology